Effects of a Nutritional Supplement Combination on Body Weight Management

October 27, 2014 updated by: Pharmanex

A Phase IV, Open-label, Parallel Group, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management Over a 90-day Period

Title: A Phase IV, Open-label, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management over a 90-day period

Study Overview

Status

Completed

Conditions

Detailed Description

Safety assessment:

Safety will be assessed by changes in blood chemistries/hematology, and adverse events, of nutritional supplement emergent AEs (TEAEs), classified by severity grade, relatedness to the nutritional supplement.

Efficacy Assessment:

The objectives of this study are to evaluate the efficacy (changes in body composition and measurements as well as influence on appetite and quality of life changes) of the nutritional supplement administered repeatedly throughout the study.

Study Subject Population:

Healthy adult men and women are eligible for participation upon fulfillment of the inclusion/exclusion criteria.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Utah
      • Orem, Utah, United States, 84058
        • Aspen Clinical Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Females and Males aged 25-65 years
  2. Signed informed consent
  3. BMI between 25 and 40 kg/m2
  4. A resting normotensive blood pressure is defined as a systolic blood pressure between 90-145 mmHg and a diastolic blood pressure of 50 90 mmHg
  5. Use of effective method of contraception by females of childbearing [potential and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study]. Acceptable methods of contraception include oral, injectable, or implantable contraceptives; intrauterine devices, diaphragm plus spermicide; abstinence (must agree to use double-barrier method if they become sexually active), transdermal patch, or any double barrier method including a vasectomized sexual partner. Women who have had a hysterectomy or tubal ligation at least 6 months prior to Visit 1 or who have been post-menopausal
  6. Ability to speak and understand English
  7. Willing to fast the morning of visit where blood samples are taken

Exclusion Criteria:

  1. Self-reported chronic condition that may affect subject safety (e.g., diabetes, cardiovascular disease) or significantly impact product effectiveness (e.g., chronic fatigue)
  2. Pregnancy/suspected pregnancy, breastfeeding or planning to become pregnant during the course of the study.
  3. Use of Antihypertensive medication for less than 4 months or unregulated clinically blood pressure.
  4. Having undergone gastroplasty or bariatric surgery in the past 10 years.
  5. Taking medication (e.g., thyroid medication), must be stable for at least four months.
  6. Allergies to any ingredients contained in the Nutritional Supplement.
  7. Medical treatment for insomnia or depression within 30-days prior to the screening visit.
  8. Tobacco (e.g. cigarettes, chewing tobacco, pipe, nicotine patches) use within 30-days prior to the screening visit.
  9. Planned surgical procedure during the course of the study.
  10. Currently participating in another study or have done so within 30 days prior to the screening visit or is likely to enroll in another clinical or nutritional study.
  11. Currently taking any medication or supplement for the use of weight loss must be discontinued prior to Visit 1 Baseline Day 0.
  12. Currently participating in a weight loss program or participated in a weight loss program in the past 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Dietary Supplement

Treatment Regimen

-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
-Evaluate the changes in body composition as determined by percent body fat using the Bod Pod
Time Frame: 90 Days
90 Days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the changes in body weight
Time Frame: 90 days
  • Determine the safety and tolerability of a weight loss system and dietary supplements containing ingredients to promote healthy weight
  • Evaluate the changes in body weight as measured by body weight and body composition changes (as determined by BMI as well as changes in body measurements-waist, hip, arm, and ankle circumferences) of a weight loss system and dietary supplements containing ingredients to promote healthy weight.
  • Determine changes in substrate energy utilization
  • Determine subjective measurements of hunger, appetite, feeling of well being during weight loss
  • Determine changes in expansion and return of blood vessels (pulse wave analyzer)
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Steve Poole, BS, Pharmanex

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2012

Primary Completion (ACTUAL)

October 1, 2014

Study Completion (ACTUAL)

October 1, 2014

Study Registration Dates

First Submitted

October 19, 2012

First Submitted That Met QC Criteria

November 8, 2012

First Posted (ESTIMATE)

November 14, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

October 29, 2014

Last Update Submitted That Met QC Criteria

October 27, 2014

Last Verified

November 1, 2012

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NSE 12-PHX-08-NU-02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Safety/Effacy

Clinical Trials on Nutritional supplement and protein shakes

Subscribe